Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA082713-02S2
Application #
6592806
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-12-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Duggineni, Srinivas; Mitra, Sayantan; Lamberto, Ilaria et al. (2013) Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Med Chem Lett 4:
Mitra, Sayantan; Duggineni, Srinivas; Koolpe, Mitchell et al. (2010) Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49:6687-95
Järvinen, Tero A H; Ruoslahti, Erkki (2010) Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice. Proc Natl Acad Sci U S A 107:21671-6
Richardson, Robyn D; Ma, Gil; Oyola, Yatsandra et al. (2008) Synthesis of novel beta-lactone inhibitors of fatty acid synthase. J Med Chem 51:5285-96
Jarvinen, Tero A H; Ruoslahti, Erkki (2007) Molecular changes in the vasculature of injured tissues. Am J Pathol 171:702-11
Zhang, Lianglin; Giraudo, Enrico; Hoffman, Jason A et al. (2006) Lymphatic zip codes in premalignant lesions and tumors. Cancer Res 66:5696-706
Browne, Cecille D; Hindmarsh, Elizabeth J; Smith, Jeffrey W (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 20:2027-35
Zhang, Lianglin; Hoffman, Jason A; Ruoslahti, Erkki (2005) Molecular profiling of heart endothelial cells. Circulation 112:1601-11
Komatsu, Masanobu; Ruoslahti, Erkki (2005) R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 11:1346-50
Ruoslahti, E; Duza, T; Zhang, L (2005) Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 11:3655-60

Showing the most recent 10 out of 35 publications